Skip to main content

Staying in treatment is critical for patients with Opioid and Substance Use Disorders.

Prescription digital therapeutics can help bridge gaps in care.

Learn More
Learn More
  • FDA-authorized to deliver Cognitive Behavioral Therapy, Fluency Training and Contingency Management

  • 24/7 access via smartphone, encourages patient engagement discreetly, anywhere, anytime  

  • Provides ability to monitor patients between appointments and is proven to help patients stay in treatment

  • Clinician Dashboard offers insights into each patient’s recovery

Provide 24/7 access to therapy
with reSET-O and reSET.
Please see Important Safety Information and Indications for Use  

How It Works

Of the 2.4 million people diagnosed with OUD in 2018, about 1 million received buprenorphine or buprenorphine-naloxone without psychotherapy.2

Of the 21.2 million Americans in need, only 17% received any formal SUD treatment.3

Clinicians face significant barriers to providing therapy.

Social Stigma

13.5% of adults who feel they need treatment for substance use cite the possible negative opinion of their community as a reason for not receiving treatment.4

Access to Therapy

A study cites 64% (n=50) of physicians who don’t prescribe buprenorphine reported lack of mental health and psychosocial support for patients as a perceived obstacle to prescribing.5

Gaps in Care

Care transitions are critical moments for patients receiving treatment for substance use. Reduced touchpoints from intensive to outpatient care settings can lead to patient drop-out.6

Contact Us

*Indicates required field.

References: 1. Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/ 2. SAMHSA/HHS: An Update on the Opioid Crisis, March 2018. https://www.samhsa.gov/sites/default/files/aatod_2018_final.pdf 3. Substance Abuse and Mental Health Services Administration. (2018). Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Center for Behavioral Health Statistics and Quality. https://www.samhsa.gov/data/  (Accessed August 2019). 4. Bose J, Hedden SL, Lipari RN, Park-Lee E. Results from the 2017 national survey on drug use and health: detailed tables. Substance Abuse and Mental Health Services Administration Website. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.htm. Accessed March 20, 2019. 5. Hutchinson E, Catlin M, Andrillas CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128-133 6. Forman RF, Nagy PD. Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. Treatment Improvement Protocol TIP 47. Rockville, MD: U.S. Dept. of Health and Human Services. 2006. DHHS Publication No. (SMA) 06-4182.